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Abstract 
 
Management of the patient with oral epithelial dysplasia depends on the ability to predict 
malignant transformation. Histological grading of this condition fails in this regard and is 
also subject to inter and intra-pathologist variability.  This study uses longitudinal clinical 
samples to explore the prognostic value of a previously validated panel of methylation 
biomarkers in a cohort of patients with histologically proven oral dysplasia. Methylation 
enrichment pyrosequencing assays were employed to provide the sensitivity of 
traditional methylation specific PCR (MSP) with the additional specificity advantages of a 
subsequent confirmatory sequencing reaction. In 57% (8/14) patients with a lesion that 
transformed to oral squamous cell carcinoma (OSCC), 26% (26/100) of longitudinal 
samples collected over ≥ 3 years demonstrated p16 methylation.  Only 1% (2/184) of 
samples from 8% of patients (2/24) not undergoing malignant transformation within 3 
years had p16 methylation.  Both of these samples with p16 promoter methylation were 
the most recently collected and the patients remain under continuing clinical review. 
Promoter methylation of MGMT, CYGB and CCNA1 did not correlate with malignant 
progression.  We thus conclude that methylation of the p16 gene promoter shows 
promise as a predictor for malignant transformation (Fishers exact P=0.002) in a subset 
of patients. 
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Introduction 
 
 
Leukoplakia and erythroplakia1 are the most common precursor lesions of oral 
squamous cell carcinoma (OSCC). Dysplasia is reported to be present in up to 25% of 
biopsies of leukoplakia whereas the majority of erythroplakia are expected to harbour 
dysplastic features which frequently amount to severe dysplasia or carcinoma in-situ2. 
Optimal management of these patients depends on the ability to predict malignant 
transformation thus allowing for closer monitoring, risk factor reduction, surgical excision 
or pharmacological intervention.  
 
The conventional management of oral epithelial dysplasia (OED) is based on 
histological grading into mild, moderate and severe dysplasia and carcinoma in-situ. 
Sites such as floor of mouth and ventral tongue, and non-homogenous and red lesions 
are cited as high risk3;4. However, only two significant prognosticators were identified in 
one recent study, namely clinical appearance of lesion and size3. The grading of 
dysplasia did not correlate with the course of the lesions, a finding reported by others5. 
Additionally, inter and intra-pathologist variability in grading of dysplasia is well described 
and may act as a confounding factor6. A further limitation in the search for predictive 
markers is the relatively low frequency (<1-18%4)  with which such premalignant lesions 
actually acquire invasive potential although this may be as high as 50% when severe 
dysplasia or carcinoma in-situ is present2.   
 
Allelic imbalance and ploidy analysis have been reported to be useful in prediction 
of progression, although neither has translated into the clinical setting.  Loss of 
heterozygosity (LOH) at 3p and 9p has been suggested to increase the risk of malignant 
progression by a factor of 3.8, whilst additional loss on chromosome arms 4q, 8p, 11q or 
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17p leads to a 33-fold increase in risk7. However a significant number of dysplastic 
lesions (47%) investigated by Tabor et al8 showed no detectable LOH and four non-
dysplastic lesions showed extensive losses. The significance of ploidy analysis remains 
controversial with the recent retraction of several prominent studies by Sudbo9;10. Some 
evidence supports ploidy abnormalities in leukoplakia although the previously reported 
prognostic importance has not been substantiated11. 
 
Few studies have investigated promoter methylation in the setting of OED. 
Unfortunately, none of the previously published reports have longitudinal clinical follow 
up and therefore cannot correlate molecular changes with malignant progression. Some 
of these studies investigated OED in clinically normal mucosa at the periphery of 
invasive squamous cell carcinoma12;13 although this strategy clearly introduces bias. 
Variable rates of p16 methylation ranging from 28% to 75% have been reported11-13,  
while methylation of the MGMT gene has been shown to be methylated in 56% of 
leukoplakia14 and in 41% of normal appearing  mucosa adjacent to tumour12.       
 
Investigation of promoter methylation of tumour suppressor genes in the setting of 
OED seems appropriate given the relatively high frequency of this epigenetic change in 
OSCC itself15 and the numerous reports of methylation in premalignant lesions at other 
sites16 including breast17, pancreas18, cervix, oesophagus19 and stomach20.  Early 
epigenetic changes could predispose cells to further genetic abnormalities that allow 
progression of the neoplastic process. For example, silencing of p16 may allow epithelial 
cells to escape senescence leading to genetic instability and permit accumulation of 
genetic mutations17 and  p16 methylation has been suggested as a valuable biomarker 
in the prediction of malignant change in gastric dysplasia20.  Furthermore, the potential 
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for demethylation and re-expression of p16 and RAR-  by 5-aza-2-deoxycytidine has 
been shown in OED cell lines21. 
 
Methods of evaluating and quantifying methylation in clinical samples continue to 
evolve. All previous studies of OED have utilised methylation specific PCR (MSP). 
Although highly sensitive, this method lacks internal control for adequacy of bisulphite 
treatment and is prone to false positives, which can occur relatively frequently, 
particularly when a high number of PCR cycles are used22. Pyrosequencing offers the 
advantage of relatively high throughput with confirmation of adequacy of bisulphite 
treatment and is semi-quantitative. Methylation enrichment pyrosequencing (MEP) is a 
relatively recently described modification of these two techniques that utilises 
methylation specific primers but is followed by a confirmatory pyrosequencing step that 
allows elimination of false positives22. This is particularly appropriate in the analysis of 
samples where target DNA concentrations may be low, such as mucosal scrapes and 
saliva. These surrogate samples have been shown to be useful in the investigation of 
oral squamous cell carcinoma (OSCC) with studies demonstrating good agreement of 
LOH patterns between OSCC and DNA extracted from saliva and lesion brushings23. 
Surrogate samples are non-invasive and seem more acceptable to the patient as a 
means of OED surveillance than continual biopsy. 
 
In order to exploit the preponderance of molecular data generated in cancer 
research to develop clinically valuable strategies in OED, two challenges are apparent. 
Firstly to identify biomarkers that predict those lesions at high risk for progression with 
high sensitivity and specificity, and second, to determine if the underlying molecular 
aberrations are amenable to pharmacological intervention.  
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The aim of this study is to explore the prognostic value of a panel of methylation 
biomarkers previously validated in OSCC15 in a cohort of patients with OED. This study 
utilises longitudinal tissue collection from a patient cohort with prolonged clinical follow-
up. We describe the utility of non-invasive oral scrapes as a surrogate for repeated 
invasive biopsies, and our assays make use of MEP in order to improve the specificity 
and sensitivity of the methylation assays. 
 
 
Materials and methods 
 
Patients 
 
Patients with biopsy proven OED were prospectively enrolled in the study subject 
to appropriate ethics and consent. Scrapes of visible leukoplakia and erythroplakia were 
obtained, as well as clinically normal, usually contralateral, oral mucosa. When multiple 
lesions were present, each was sampled separately. Patients whose lesions were 
perceived to be at high risk based on existing clinical criteria underwent surgical 
excision.  These patients were retained within the observed cohort and the surgical site 
or any residual lesion subsequently sampled after healing. Scrapes were obtained using 
faecal sampling spoons, snap frozen in liquid nitrogen and stored at -80°C.  Re-biopsy 
was performed as clinically indicated and, if sufficient tissue was available, a portion was 
separated and snap frozen in liquid nitrogen for research use. Clinical parameters, site 
and past medical and habit history were recorded.  
 
Analysis of clinical data from all enrolled patients diagnosed between 2000 and 
2003 was undertaken in 2006 to establish 2 cohorts. Firstly, a subset of 24 patients was 
identified with stable or non-transforming dysplasia (“NT” group). The criteria for 
inclusion were a histological diagnosis of dysplasia in a patient who had been followed 
for a period of at least 36 months with no evidence of clinical or histological progression, 
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or perhaps even regression. The second sample set (transformers: “T”) consisted of 14 
patients who, following a biopsy diagnosis of dysplasia, developed invasive carcinoma at 
the same site at a time interval of at least 6 months following the index biopsy. This time 
criteria allowed exclusion of an inadequate or non-representative biopsy. For those 
patients with multiple pre-malignant lesions, development of carcinoma at any one of the 
sites triggered inclusion to the transforming group.  In total, 284 scrape samples were 
collected from 38 patients with OED over 3 years (NT group mean: 7.6, median: 8, 
range: 2-15 samples per patient.  T group mean: 7.1, median: 8, range 2-25 samples per 
patient). 
DNA extraction 
For both scrapes and tissue samples, DNA was extracted using a phenol-
chloroform based extraction procedure which gives superior yield from small samples24. 
Bisulphite treatment of each sample was undertaken using the EZ DNA methylation kit 
(Zymo Research). A quality check of converted DNA was performed using 
pyrosequencing methylation assay (PMA) primers15 specific for bisulphite treated DNA, 
which confirmed the DNA content prior to analysis and assessed the efficiency of 
bisulphite conversion using an internal control (a C residue not followed by a G residue 
in the sequence being examined, which will not be subject to methylation and therefore 
should be completely converted to Uracil).  Any samples showing less than 100% 
conversion were rejected as these are likely to produce false +ves in any methylation 
dependent assay.   
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Methylation analysis  
 
Methylation enrichment pyrosequencing (MEP) was employed as previously 
described22. Hot-start PCR was carried out with HotStar Taq® Master Mix Kit (Qiagen 
Ltd.) using 120ng bisulphite treated DNA. MEP primers and annealing temperatures are 
shown in Table 1.  PCR conditions were as follows: 1 cycle at 94oC for 15 minutes; 40 
cycles of [94oC for 30 seconds, annealing temperature for 30 seconds, 72oC for 30 
seconds]; 1 cycle of 72oC for 5 minutes. The presence or absence of PCR products and 
freedom from PCR contamination was established on 2% agarose gels with ethidium 
bromide staining. Gel-positive PCR products were subject to confirmatory 
pyrosequencing to ensure that methylation was >95% at all CpG dinucleotides 
interrogated. This constituted our criterion for designation of a sample as „methylation 
positive‟. These specific CpG targets in 4 genes have previously been demonstrated to 
be methylated in a  tumour specific pattern in OSCC15. Pyrosequencing was carried out 
using the PSQ96MA System (Biotage) according to manufacturer‟s protocol, as 
previously described15.  
Statistical analysis 
 
Differences in methylation frequency between NT and T groups were tested using 
Fishers Exact test. Tests involving samples were not undertaken because 
interdependence of samples from the same patient was assumed. Differences in the 
number of methylated genes between NT & T patient groups were tested using the 
Mann-Whitney Test.  
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Results 
 
Clinical 
 
 Of the 24 patients in the NT group, 13 (54%) had mild, 5 (21%) moderate and 6 
(25%) had severe OED on the initial biopsy. Of the 14 patients in the T group 6 (43%) 
had mild, 3 (21%) moderate and 5 (36%) severe OED, although several patients 
underwent subsequent biopsies that showed a progression to a higher grade. The 
differences were not significant. There was also no significant difference in the 
distribution of affected sub-sites between NT and T groups (data not shown). Smoking 
history was obtained in 22 of the 24 NT patients. Only 2 had never smoked, most having 
sustained the habit over a prolonged (>20 year) period. Four of the 14 T patients denied 
ever smoking, 6 were current long term smokers and there were 3 ex-smokers. 
  
Gene promoter methylation analysis 
 
In total, 293 gel positives were obtained from all investigated genes, of which 65% 
were eliminated either as unmethylated or as non-target PCR products (i.e. the 
pyrosequencing reaction failed).  
p16 
 
Methylation of the p16 promoter predicted for malignant transformation, being 
present in 26% (26/100) of samples from T patients compared with 1% (2/184) of 
samples from the NT group (Table 2). Overall, 57% of patients from the T group were 
positive in at least one scrape compared with only 8% of patients from the NT group 
(Fishers Exact P=0.002).  Furthermore, this p16 promoter methylation was retained in 
subsequent samples in 4/5 patients where the first sample testing positive was not the 
most recently collected. Almost twice as many of the positive samples in the T group 
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were from lesions than from normal tissue (Table 3).  Notably, only 2 samples showed 
p16 promoter methylation amongst the NT group and these samples were the most 
recently collected from those patients.  Transforming patients who demonstrated 
methylation of the p16 promoter (n=8; Table 2) displayed variable time intervals between 
their first presentation of p16 promoter methylation and the development of OSCC 
(range 0-70 months; median 18 months) which did not appear to correlate with 
pathological staging.    
Cyclin A1 (CCNA1) 
 
Methylation at this gene promoter was similar between T (50%) and NT (58%) 
patient cohorts (Table 2), however, a tendency for methylation in the T samples was 
observed (12% vs. 22%).  Within both groups, the majority of positive samples were 
derived from clinically apparent lesions (Table 3). 
 
Cytoglobin (CYGB) 
 
Methylation at CYGB was frequent in both cohorts, seen in 46% and 57% of 
patients in the NT and T groups respectively (Table 2). Methylation was seen in 10% of 
NT samples compared with 25% of samples from the T group.  Methylation was 
observed more consistently in longitudinal samples from the T group, whereas a more 
sporadic distribution of positive results were seen in the NT group, leading to the 
frequency of positive samples from normal and lesional tissue shown in Table 3.  
 
MGMT 
 
MGMT showed the lowest level of methylation with only 3% and 4% of NT and T 
samples respectively being positive, corresponding to 21% and 29% of patients. The 
positive samples were usually solitary findings amongst multiple negative samples thus 
explaining the discrepancy between the percentages of positive samples and patients.  
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Methylation at multiple gene promoters 
 
The number of genes showing promoter methylation in each patient was 
compared between the two groups (Table 4). Methylation of one gene appeared to be a 
relatively frequent event amongst stable (NT) patients. A higher proportion of patients 
with 3 or 4 methylated gene promoters was observed in the T group (6/14 vs 1/24, T vs 
NT) but this was not significant. Neither single gene methylation, nor an overall pattern of 
increasing methylation correlated with the histological grade of malignancy (data not 
shown).  
 
Methylation in oral scrapes vs corresponding biopsy tissue 
 
Where both incisional biopsy and corresponding scrape material was available 
from the same lesion, a comparison was made of methylation status between the two 
sources of DNA. Concordance of methylation status between scrape and tissue was 
seen in 80% of cases (61 concordant results, 15 non-concordant). Interestingly, in the 
discrepant cases the scrape was more likely to show positivity than the biopsy, perhaps 
reflecting a masking of methylation in dysplastic cells by contaminating unmethylated 
DNA from stroma and inflammatory cells in the latter samples.  
 
 
Discussion 
 
This study demonstrates that methylation of p16 in oral epithelial dysplasia (OED) 
is potentially a specific predictive marker of malignant transformation. However, it has 
limited sensitivity as only 57% of the transforming patients showed this change. In our 
cohort, histological grading of dysplasia neither correlated with development of invasive 
carcinoma, in keeping with previous reports3, nor with p16 promoter methylation. Our 
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study is the first to analyse methylation patterns in multiple longitudinal samples from 
OED patients with no previous history of oral squamous cell carcinoma (OSCC), and 
who were later divisible on the basis of remaining stable for more than 36 months or 
showing progression to carcinoma. However, no clear conclusions could be drawn about 
the timing of p16 promoter methylation and disease progression in this small sample of 
patients, although this is clearly an important consideration when determining the 
suitability of p16 promoter methylation as a potential biomarker. 
 
The OED/OSCC continuum provides a model in which to study molecular 
aberrations triggering malignant change in pre-cancerous states. The study of disease 
progression at any site is often limited by the difficulty in obtaining samples from the 
same lesion over time and correlation with clinical and histological change. The 
opportunities offered by the oral cavity are its relative accessibility and the ability to 
obtain surrogate tissue samples such as mucosal scrapes and saliva. Few previous 
studies have investigated methylation in the setting of OED and most have used MSP 
which is prone to false positive results22. This was highlighted in our study by the 
proportion of samples in which “gel positive” products were subsequently rejected 
following pyrosequencing. These failures include priming from unmethylated alleles thus 
generating unmethylated products and mispriming, which is known to be a problem with 
low concentrations of target DNA and high numbers of PCR cycles. MEP offers several 
advantages in clinical samples of this type. A relatively large sample set can be 
processed at moderate cost since only „gel positive‟ samples require the confirmatory 
pyrosequencing step. Validation by pyrosequencing allows the exclusion of all false 
positive results and also checks for adequacy of bisulphite conversion. Furthermore, the 
quantity of DNA obtained from a mucosal scrape may be small and will almost certainly 
include contaminating oral tissue and salivary DNA. In these situations, MEP is an ideal 
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technique due to its high sensitivity and ability to detect methylation in clinical samples 
with low concentrations of methylated DNA. 
 
p16 promoter methylation offers promise as a predictive biomarker differentiating 
between stable and transforming OED. It is noteworthy that in the two NT patients 
demonstrating p16 methylation, the change was detected only in the most recent 
sample. Attempts to compare our data with other published studies are difficult due to 
differences in methods and lack of clinical follow-up in the literature. Kresty et al25 
reported methylation of p16 in 58% patients with severe dysplasia while Lopez noted 
relatively high rates of methylation at p16 (44%) and MGMT (56%) in DNA extracted 
from mouthrinse14, and for p16 this was slightly increased in patients with persistent 
leukoplakia and a history of OSCC.  p16 was shown to be methylated in 75% of OED 
patients enrolled in a chemopreventive trial13, with 38% demonstrating reversal during 
the course of the study. However, correlation of methylation with outcome was not 
specifically stated and an apparent association between methylation and increasing 
severity of dysplasia was noted, in contrast to our findings., More recently, Kato and 
colleagues12 determined methylation status of p16 and MGMT in OSCC, tumour 
adjacent mucosa, and mucosa from healthy volunteers. No methylation was found in the 
latter group, but it was present at high rates in OSCC (51% and 56% for p16 and MGMT 
respectively). Clinically normal oral mucosa adjacent to tumour showed an intermediate 
frequency of methylation (27% and 40%).  In our current study 26% of all patients 
demonstrated p16 methylation, clearly at the lower end of the previously reported rates 
(27-75%). One explanation may be false positive MSP results in previous studies. The 
prevalence of p16 methylation in our previous (unrelated) cohort of OSCC patients 
(27%)15 was lower than that of our transforming cohort of OED (57%). This might 
suggest that p16 methylation may be more common in OED-derived OSCC, or perhaps 
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represents a transient stage in malignant transformation. However we are cautious in 
this conclusion because in our previous study the criteria for p16 methylation in tumour 
tissue were significantly more stringent than in this study (>5% methylation using a 
quantitative assay [PMA] compared with a qualitative [yes/no] assay [MEP]). 
 
To our knowledge, this is the first study that investigates CCNA1 and CYGB in 
OED. Although methylation at the promoters of these genes was prevalent in OED, this 
did not predict malignant transformation. Our data for MGMT conflicts with that 
previously published in OED with very few samples showing methylation (3% and 4%). 
In a cohort of OSCC in which the same CpG islands were analysed15, 31% of patients 
were methylated at this gene. One possible explanation is that silencing of this gene 
occurs at a later stage and that methylation does not contribute to acquisition of 
dysplasia or early invasion. Alternatively, it is well recognised that a subset of OSCC 
may arise de-novo without any clinically or histologically detectable lesion, and 
abnormalities of MGMT may represent a subset of tumours with no clinically 
recognisable premalignant state.  
 
In this study, the finding of methylation rates between 23-50% in clinically normal 
mucosa from OED patients (Table 3) is in keeping with concept of field change26 and 
implies that molecular aberrations extend far beyond the limits of histological and clinical 
detection.  As previously reported, the histological grade of dysplasia did not predict 
malignant transformation3 but notably there were a higher proportion of non-smokers 
amongst the T group. This is consistent with the findings that although smoking is a risk 
factor for development of OED, the habit appears not to be associated with additional 
cancer risk27. This is also corroborated by our previous work, which demonstrated 
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methylation at the p16 gene in only 4% of clinically/histologically normal mucosa from 70 
patients, 57% of whom were heavy smokers15.  
 
Limitations of the present study include the small number of genes selected for 
study and the relatively small size of the cohort. The 4 genes chosen for analysis were 
selected from 10 reported in the literature as most frequently methylated in OED and 
OSCC28, and were subjected to validation as tumour specific by pyrosequencing 15. In 
order to address the lack of sensitivity of a single methylation marker such as p16 in 
predicting transformation, global methylation analysis may prove helpful in the selection 
of additional markers and such methods are rapidly evolving.  
 
Confirmatory studies are now required in other cohorts to validate that p16 
methylation is seen specifically in transforming patients and additional methylation 
markers are required in order to form a clinically useful  predictive panel. This study also 
suggests that there is some merit in investigating demethylating agents in OED, perhaps 
delivered topically. Methylation assay of mucosal scrapes would provide a surrogate 
endpoint, at least to demonstrate pharmacological effect. Our findings may also have 
generalised relevance in other upper aerodigestive tract malignancies such as laryngeal, 
oesophageal and bronchial squamous cell carcinoma which have common aetiological 
factors and similar histological appearances in both the premalignant and invasive 
stages.    
 
In summary, this is the first study to apply sensitive methylation assays to serial 
OED scrape samples with corresponding clinical outcome data. Promoter methylation of 
p16 is a promising biomarker for malignant transformation in OED. 
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Gene Forward primer  Reverse primer Pyrosequencing 
primer 
Annealing 
Temperature 
CCNA1 
Biotin-
TTTGCGTAGTTTCGAGGATTTC 
CCGTTCTCCCAACAACCG CTAACAACCCCCTCTA 60
O
C 
CYGB Biotin-TCGATCGTTAGTTCGTTC ACTAACTCGAAAACGCG ACCCAACTAAATCCAC 56
O
C 
P16 
CGGAGGGGGTTTTTTCGTTAGTATC Biotin-
TCCCCCTCTCCGCAACCG 
GGTTGGTTATTAGAGGGT 62
O
C 
MGMT 
CGGTTTCGTTTTCGCGTTTC Biotin-
ACCGCGAAAACCTACGAACG 
GGATATGTTGGGATAGT 62
O
C 
 
Table 1 
Gene PCR and pyrosequencing primers and PCR annealing temperature. 
CCNA1: cyclin A1; CYGB: cytoglobin; MGMT: 6-O-methylguanine DNA methyltransferase. 
Biotin: the indicated primers were 5‟ biotin labelled to enable preparation of the appropriate single stranded DNA 
for subsequent pyrosequencing reactions. 
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CCNA1 CYGB p16 
 
MGMT 
 
NT T NT T NT T NT T 
 
Samples 
 
22/184 
(12%) 
22/100 
(22%) 
18/184 
(10%) 
25/100 
(25%) 
2/184 
(1%) 
26/100 
(26%) 
6/184 
(3%) 
4/100 
(4%) 
 
Patients  
 
14/24 
(58%) 
7/14 
(50%) 
11/24 
(46%) 
8/14 
(57%) 
2/24 
(8%) 
8/14 
(57%) 
5/24 
(21%) 
4/14 
(29%) 
Fishers 
Exact 
test* 
P=0.74 P=0.74 P=0.002 P=0.70 
 
Table 2 
Frequency of gene promoter methylation in the non-transforming (NT) and transforming 
(T) cohorts.  Results are summarised for total samples and for individual patients in 
separate rows. 
CCNA1: cyclin A1; CYGB: cytoglobin; MGMT: 6-O- methylguanine-DNA 
methyltransferase 
*: Fishers Exact test relates to patient data (see materials and methods). 
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CCNA1 
 
CYGB p16 MGMT 
 N D N D N D N D 
NT 
5/22 
(23%) 
17/22 
(77%) 
9/18 
(50%) 
9/18 
(50%) 
1/2 
(50%) 
1/2 
(50%) 
3/6 
(50%) 
 
3/6 
(50%) 
 
T 
 
5/22 
(23%) 
17/22 
(77%) 
5/25 
(20%) 
20/25 
(80%) 
9/26 
(35%) 
17/26 
(65%) 
2/4 
(50% 
 
2/4 
(50%) 
 
NT + T  
 
 
10/44 
(23%) 
 
24/44 
(55%) 
14/43 
(33%) 
29/43 
(67%) 
10/28 
(36%) 
18/28 
(64%) 
5/10 
(50%) 
5/10 
(50%) 
 
 
 
Table 3 
Distribution of gene promoter methylation in normal (N) and dysplastic (D) lesions in the 
non-transforming (NT) and transforming (T) cohorts    
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Methylation 
 -ve 
 
1 gene 
+ve 
2 genes 
+ve 
3 genes 
+ve 
4 genes 
+ve 
NT 
(n=24)  
 
3 (13%) 
 
12 (50%) 8 (33%) 
 
1(4%) 0 (0%) 
T  
(n=12) 
 
4 (29%) 
 
3 (21%) 1 (7%) 
 
2 (14%) 4 (29%) 
 
 
Table 4 
Frequency of multiple gene promoter methylation in the non-transforming (NT) and 
transforming (T) cohorts 
 
